Please note, this OEL/ADE monograph also applies to lasofoxifene hydrochloride (CAS RN 180915-85-9), and lasofoxifene tartrate (CAS RN 190791-29-8). Lasofoxifene is indicated for treatment of postmenopausal osteoporosis. Lasofoxifene improves bone strength and reduces fracture risk by decreasing bone turnover, resulting in stabilization or an increase in bone mineral density, preservation of bone microarchitecture , reduction in trabecular perforation and a decrease in cortical porosity.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API).
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL monograph for Lasofoxifene, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.